[go: up one dir, main page]

CO5570662A2 - Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo - Google Patents

Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo

Info

Publication number
CO5570662A2
CO5570662A2 CO04037005A CO04037005A CO5570662A2 CO 5570662 A2 CO5570662 A2 CO 5570662A2 CO 04037005 A CO04037005 A CO 04037005A CO 04037005 A CO04037005 A CO 04037005A CO 5570662 A2 CO5570662 A2 CO 5570662A2
Authority
CO
Colombia
Prior art keywords
methyl
phenol
dimethylamino
ethyl
weight
Prior art date
Application number
CO04037005A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5570662(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CO5570662A2 publication Critical patent/CO5570662A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Formulación farmacéutica de liberación lenta, que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmacéuticamente aceptable del mismo en una matriz con liberación lenta del ingrediente activo, donde la matriz contiene de un 1% a un 80% en peso de uno o más polímeros hidrófilos o hidrófobos como agentes formadores de matriz farmacéuticamente aceptables y tiene la siguiente velocidad de liberación in vitro, medida mediante el Método Paddle Ph. Eur. a 75 rpm en un tampón (de acuerdo a Ph. Eur.) a un pH de 6,8 a 37°C y detectada mediante un espectrómetro UV:de un 3% a un 35% en peso (sobre la base del 100% del peso del ingrediente activo) de 3-(3-dimetilamino-1-etil-2-metil-propil) fenol liberado después de 0,5 horas, de un 5% a un 50% en peso de 3-(3-dimetilamino-1-etil-2-metil-propiI) fenol liberado después de 1 hora, de un 10% a un 75% de 3-(3-dimetilamino-1-etil-2-metil-propil) fenol liberado después de 2 horas, de un 15% a un 82% en peso de 3-(3-dimetilamino-1-etil-2-metiI-propil) fenol después de 3 horas,de un 30% a un 97% en peso de 3-(3-dimetilamino-1-etil-2-metil-propil) fenol después de 6 horas,más de un 50% en peso de 3-(3-dimetilamino-1-etil-2-metil-propiI) fenol liberado después de 12 horas,más de 70% en peso de 3-(3-dimetilamino-1-etil-2-metil-propil) fenol liberado después de 18 horas, más de un 80% en peso de 3-(3-dimetilamino-1-etil-2-metil-propil) fenol liberado después de 24 horas.
CO04037005A 2001-10-24 2004-04-22 Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo CO5570662A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
CO5570662A2 true CO5570662A2 (es) 2005-10-31

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04037005A CO5570662A2 (es) 2001-10-24 2004-04-22 Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo

Country Status (28)

Country Link
US (7) US20050058706A1 (es)
EP (1) EP1439829B1 (es)
JP (2) JP4758064B2 (es)
KR (1) KR100958045B1 (es)
CN (1) CN100402021C (es)
AR (1) AR036943A1 (es)
AT (1) ATE303802T1 (es)
AU (1) AU2002349001C1 (es)
BR (1) BRPI0213653B8 (es)
CA (1) CA2464578C (es)
CO (1) CO5570662A2 (es)
CY (1) CY2012022I2 (es)
DE (1) DE50204198D1 (es)
DK (1) DK1439829T3 (es)
EC (1) ECSP045102A (es)
ES (1) ES2248622T3 (es)
HU (1) HU230161B1 (es)
IL (2) IL161587A0 (es)
MX (1) MXPA04003742A (es)
MY (1) MY127797A (es)
NO (2) NO331896B1 (es)
NZ (1) NZ532999A (es)
PE (1) PE20030527A1 (es)
PL (1) PL216535B1 (es)
PT (1) PT1439829E (es)
SI (1) SI1439829T1 (es)
WO (2) WO2003035054A1 (es)
ZA (1) ZA200403928B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
PT1562567T (pt) 2002-11-22 2017-08-24 Gruenenthal Gmbh Combinação de analgésicos selecionados e inibidores da cox-ii
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
EP1786403B1 (de) * 2004-07-01 2013-07-24 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ571442A (en) * 2006-04-28 2011-09-30 Gruenenthal Chemie Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol for treating pain
CN102671195B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
ES2623413T3 (es) * 2007-12-07 2017-07-11 Grünenthal GmbH Modificaciones cristalinas de (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
JP6216489B2 (ja) 2008-10-30 2017-10-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 新規の、効力のあるタペンタドール剤形
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2555756B1 (en) * 2010-04-07 2018-08-22 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011138037A2 (de) * 2010-05-05 2011-11-10 Ratiopharm Gmbh Festes tapentadol in nicht-kristalliner form
KR101831616B1 (ko) * 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
EP2588093B1 (en) 2010-06-30 2016-06-15 Grünenthal GmbH Tapentadol for use in the treatment of irritable bowel syndrome
MX341072B (es) 2010-07-23 2016-08-05 Grünenthal Gmbh * Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
CA2828637C (en) 2011-03-04 2019-06-11 Grunenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
KR101970468B1 (ko) 2011-03-04 2019-04-19 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여
KR102051800B1 (ko) 2011-03-04 2019-12-04 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
PL2694049T3 (pl) 2011-04-05 2019-07-31 Grünenthal GmbH Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
PT2701693T (pt) 2011-04-29 2017-11-16 Gruenenthal Gmbh Tapentadol para prevenção e tratamento de depressão e ansiedade
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
PL2736501T3 (pl) * 2011-07-29 2018-06-29 Grünenthal GmbH Dooponowe lub nadtwardówkowe podawanie 3-[(1S,2S)-3-(dimetyloamino)-1-etylo-2-metylopropylo]fenolu
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
PT3273953T (pt) 2015-03-27 2019-04-01 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
WO2018219897A1 (en) * 2017-05-29 2018-12-06 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875077B1 (en) 2020-03-02 2023-12-13 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875080A1 (en) * 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
BR112022017700A2 (pt) 2020-03-02 2023-01-17 Gruenenthal Gmbh Forma de dosagem fornecendo liberação prolongada de sal de ácido fosfórico de tapentadol
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
HUE059465T2 (hu) 2020-11-10 2022-11-28 Gruenenthal Gmbh A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája
WO2022101247A1 (de) 2020-11-10 2022-05-19 Grünenthal GmbH Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5567587A (en) 1983-01-10 1996-10-22 Gen-Probe Incorporated Method for detecting, the presence and amount of prokaryotic organisms using specific rRNA subsequences as probes
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
KR100329256B1 (ko) 1993-11-17 2002-11-04 미츠비시 파마 코포레이션 병변이상조직 치료용 조성물,그의 제조방법 및 용도
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
DE69739165D1 (de) * 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
EP2295043A1 (en) * 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
ES2248622T3 (es) 2006-03-16
PL369756A1 (en) 2005-05-02
SI1439829T1 (sl) 2006-02-28
KR20040047964A (ko) 2004-06-05
BRPI0213653B1 (pt) 2018-04-03
AU2002349001B2 (en) 2003-05-06
MXPA04003742A (es) 2004-07-23
JP2010280697A (ja) 2010-12-16
NO20041924L (no) 2004-05-11
DE50204198D1 (de) 2005-10-13
ZA200403928B (en) 2005-07-27
US20170087103A1 (en) 2017-03-30
BRPI0213653B8 (pt) 2021-05-25
EP1439829A1 (de) 2004-07-28
AR036943A1 (es) 2004-10-13
JP4758064B2 (ja) 2011-08-24
PT1439829E (pt) 2005-11-30
NO331896B1 (no) 2012-04-30
CN1607947A (zh) 2005-04-20
US20130237608A1 (en) 2013-09-12
CN100402021C (zh) 2008-07-16
IL161587A (en) 2009-12-24
US20200038344A1 (en) 2020-02-06
CA2464578C (en) 2011-10-11
US11007156B2 (en) 2021-05-18
JP2005506367A (ja) 2005-03-03
CY2012022I1 (el) 2015-08-05
US20160151309A1 (en) 2016-06-02
ATE303802T1 (de) 2005-09-15
BR0213653A (pt) 2004-10-26
CA2464578A1 (en) 2003-05-01
HUP0402104A2 (hu) 2005-03-29
CY2012022I2 (el) 2015-08-05
EP1439829B1 (de) 2005-09-07
US20180221308A1 (en) 2018-08-09
PE20030527A1 (es) 2003-07-26
NO2012007I1 (no) 2012-05-21
MY127797A (en) 2006-12-29
WO2003035053A1 (de) 2003-05-01
DK1439829T3 (da) 2005-10-10
IL161587A0 (en) 2004-09-27
NO2012007I2 (no) 2013-01-02
US20050058706A1 (en) 2005-03-17
PL216535B1 (pl) 2014-04-30
ECSP045102A (es) 2004-06-28
AU2002349001C1 (en) 2022-04-14
WO2003035054A1 (de) 2003-05-01
NZ532999A (en) 2007-06-29
US20120034304A1 (en) 2012-02-09
KR100958045B1 (ko) 2010-05-17
HU230161B1 (en) 2015-09-28
HK1068539A1 (en) 2005-04-29

Similar Documents

Publication Publication Date Title
CO5570662A2 (es) Formulacion farmaceutica que contiene 3-(3-dimetilamino-1- etil-2-metil-propil) fenol y proporciona una liberacion retardada del ingrediente activo
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
WO2008107149A3 (de) Darreichungsform mit erschwertem missbrauch
YU23402A (sh) Kompozicije sa kontrolisanim oslobađanjem koje sadrže nimezulid
ES2331046T1 (es) Formulacion de liberacion controlada.
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BR0208183A (pt) Peptìdeo modificado por wt1
AR065073A2 (es) Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
ATE476997T1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
ECSP088285A (es) 3-(2-dimetilaminometil ciclohexil) fenol formulación retardada.
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas
ATE491452T1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung
HRP20080252T3 (hr) Oralni antimikrobni farmaceutski pripravci
MX2009001231A (es) Implantes subcutaneos que liberan un principio activo durante un periodo de tiempo extendido.
AR067450A1 (es) Composicion faramaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina
AR104921A2 (es) Formulación farmacéutica con liberación retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmacéuticamente aceptable del mismo y tabletas para administración oral, que la contienen
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.

Legal Events

Date Code Title Description
FC Application refused